Diflomotecan

DB16138InvestigationalSmall molecule

Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).

Mechanism: Pharmacologically active on DNA topoisomerase 1
Curator reviewed
Formula / weight: C₂₁H₁₆F₂N₂O₄ · 398.366 g/mol (avg)

Resolves to

Compound

UNIIQKT1LC4J1PCAS220997-97-7ChEMBLCHEMBL306280ChEBI144046

Structure

InChIKeyLFQCJSBXBZRMTN-OAQYLSRUSA-NSMILESCC[C@@]1(O)CC(=O)OCC2=C1C=C1N(CC3=CC4=CC(F)=C(F)C=C4N=C13)C2=O

Targets

P11387TOP1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Diflomotecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account